83 related articles for article (PubMed ID: 10472354)
1. 99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours.
Bakker M; van der Graaf WT; Piers DA; Franssen EJ; Groen HJ; Smit EF; Kool W; Hollema H; Müller EA; De Vries EG
Anticancer Res; 1999; 19(3B):2349-53. PubMed ID: 10472354
[TBL] [Abstract][Full Text] [Related]
2. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi.
Chen CC; Meadows B; Regis J; Kalafsky G; Fojo T; Carrasquillo JA; Bates SE
Clin Cancer Res; 1997 Apr; 3(4):545-52. PubMed ID: 9815718
[TBL] [Abstract][Full Text] [Related]
3. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo.
Luker GD; Fracasso PM; Dobkin J; Piwnica-Worms D
J Nucl Med; 1997 Mar; 38(3):369-72. PubMed ID: 9074520
[TBL] [Abstract][Full Text] [Related]
4. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients.
Vecchio SD; Ciarmiello A; Potena MI; Carriero MV; Mainolfi C; Botti G; Thomas R; Cerra M; D'Aiuto G; Tsuruo T; Salvatore M
Eur J Nucl Med; 1997 Feb; 24(2):150-9. PubMed ID: 9021112
[TBL] [Abstract][Full Text] [Related]
5. Characterization of P-glycoprotein transport and inhibition in vivo.
Barbarics E; Kronauge JF; Cohen D; Davison A; Jones AG; Croop JM
Cancer Res; 1998 Jan; 58(2):276-82. PubMed ID: 9443405
[TBL] [Abstract][Full Text] [Related]
6. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.
Agrawal M; Abraham J; Balis FM; Edgerly M; Stein WD; Bates S; Fojo T; Chen CC
Clin Cancer Res; 2003 Feb; 9(2):650-6. PubMed ID: 12576431
[TBL] [Abstract][Full Text] [Related]
7. Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy.
Taki J; Sumiya H; Asada N; Ueda Y; Tsuchiya H; Tonami N
J Nucl Med; 1998 Jul; 39(7):1179-84. PubMed ID: 9669390
[TBL] [Abstract][Full Text] [Related]
8. Technetium-99m sestamibi imaging in paediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein.
De Moerloose B; Van de Wiele C; Dhooge C; Philippé J; Speleman F; Benoit Y; Laureys G; Dierckx RA
Eur J Nucl Med; 1999 Apr; 26(4):396-403. PubMed ID: 10199946
[TBL] [Abstract][Full Text] [Related]
9. Reversal of multidrug resistance: lessons from clinical oncology.
Bates SF; Chen C; Robey R; Kang M; Figg WD; Fojo T
Novartis Found Symp; 2002; 243():83-96; discussion 96-102, 180-5. PubMed ID: 11990784
[TBL] [Abstract][Full Text] [Related]
10. Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors.
Kostakoglu L; Elahi N; Kïratlï P; Ruacan S; Sayek I; Baltalï E; Sungur A; Hayran M; Bekdik CF
J Nucl Med; 1997 Jul; 38(7):1003-8. PubMed ID: 9225779
[TBL] [Abstract][Full Text] [Related]
11. Scintigraphic detection of multidrug resistance in cancer.
Del Vecchio S; Ciarmiello A; Salvatore M
Cancer Biother Radiopharm; 2000 Aug; 15(4):327-37. PubMed ID: 11041017
[TBL] [Abstract][Full Text] [Related]
12. Wash-out kinetics of 99mTc-MIBI and the scintigraphic determination of Pgp expression: reply.
Del Vecchio S; Ciarmiello A; Salvatore M
Eur J Nucl Med; 1998 Feb; 25(2):192. PubMed ID: 9537801
[No Abstract] [Full Text] [Related]
13. Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein.
Crankshaw CL; Marmion M; Luker GD; Rao V; Dahlheimer J; Burleigh BD; Webb E; Deutsch KF; Piwnica-Worms D
J Nucl Med; 1998 Jan; 39(1):77-86. PubMed ID: 9443741
[TBL] [Abstract][Full Text] [Related]
14. Functional imaging of multidrug resistance in an orthotopic model of osteosarcoma using 99mTc-sestamibi.
Gomes CM; Welling M; Que I; Henriquez NV; van der Pluijm G; Romeo S; Abrunhosa AJ; Botelho MF; Hogendoorn PC; Pauwels EK; Cleton-Jansen AM
Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1793-803. PubMed ID: 17541583
[TBL] [Abstract][Full Text] [Related]
15. 99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis.
Yüksel M; Cermik TF; Doğanay L; Karlikaya C; Cakir E; Salan A; Berkarda S
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):876-81. PubMed ID: 12111127
[TBL] [Abstract][Full Text] [Related]
16. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
[TBL] [Abstract][Full Text] [Related]
17. Detection of P-glycoprotein activity in endotoxemic rats by 99mTc-sestamibi imaging.
Wang JH; Scollard DA; Teng S; Reilly RM; Piquette-Miller M
J Nucl Med; 2005 Sep; 46(9):1537-45. PubMed ID: 16157538
[TBL] [Abstract][Full Text] [Related]
18. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression.
Cordobes MD; Starzec A; Delmon-Moingeon L; Blanchot C; Kouyoumdjian JC; Prévost G; Caglar M; Moretti JL
J Nucl Med; 1996 Feb; 37(2):286-9. PubMed ID: 8667063
[TBL] [Abstract][Full Text] [Related]
19. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer.
Kostakoglu L; Kiratli P; Ruacan S; Hayran M; Emri S; Ergün EL; Bekdik CF
J Nucl Med; 1998 Feb; 39(2):228-34. PubMed ID: 9476923
[TBL] [Abstract][Full Text] [Related]
20. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients.
Del Vecchio S; Ciarmiello A; Pace L; Potena MI; Carriero MV; Mainolfi C; Thomas R; D'Aiuto G; Tsuruo T; Salvatore M
J Nucl Med; 1997 Sep; 38(9):1348-51. PubMed ID: 9293785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
